MorphoSys AG (MOR.DE)
- EQS Group
MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
EQS-News: MorphoSys AG / Key word(s): ConferenceMorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024 09.01.2023 / 07:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, January 9, 2023 MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that topline data from the ongoing Phase 3 MA
- Simply Wall St.
Investors in MorphoSys (ETR:MOR) have unfortunately lost 90% over the last three years
As every investor would know, not every swing hits the sweet spot. But really big losses can really drag down an...
- EQS Group
MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
EQS-News: MorphoSys AG / Key word(s): ForecastMorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability 05.01.2023 / 11:38 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release Planegg/Munich, Germany, January 5, 2023 MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability Preliminary 2022 Monjuvi U.S. net prod
